ABclonal Technology Joins YCharOS Industry Advisory Committee to Tackle Reproducibility Crisis in Biomedical Research
BOSTON, March 21, 2022 /PRNewswire/ -- ABclonal Technology, a rapidly growing life science research and diagnostic reagents manufacturer, today announced it has joined the Industry Advisory Committee (IAC) at YCharOS Inc., an open science company with the mission of characterizing commercially available antibody reagents for all human proteins, to tackle the reproducibility crisis observed in biomedical research. Inconsistent antibody...
RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which specializes in the development of mRNA (messenger ribonucleic acid)-based therapeutics, announced today that it has signed a Collaborative Research Agreement with PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics. Under the agreement, both companies will collaborate to...
KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
SYDNEY, March 21, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. American Association of Cancer Research Annual Scientific Meeting Four abstracts relating to Kazia's pipeline have been accepted for presentation at the upcoming American Association...
INTERVAPOR®, THERMAL VAPOR TREATMENT SYSTEM, APPROVED FOR MARKETING IN CHINA
HANGZHOU, China, March 21, 2022 /PRNewswire/ -- Broncus(02216HK) today is pleased to announce that InterVapor® (including InterVapor Generator and InterVapor Catheter, the "InterVapor®"), the Company's thermal vapor treatment system, has been granted approval by the National Medical Products Administration of China (the "NMPA"), denoting the official commercialization of the world's only such product in China. This is the first NMPA-approved...
Leading health solutions provider TruDoc appoints two new CEOs amid Middle East and Africa expansion
DUBAI, UAE, March 21, 2022 /PRNewswire/ -- TruDoc, the UAE's leading telehealth and Hospital at home health services provider, is proud to announce the appointment of two regional CEOs as it continues to expand its service portfolio across the Middle East, Africa and Asia. Effective immediately, Hisham Radwan has been appointed TruDoc CEO...
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royalties Nuance Pharma obtains rights to commercialize MVA-BN® RSV in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and Southeast Asia and will be responsible for all costs, including development and regulatory Bavarian Nordic will manufacture and...
David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access
LONDON, March 21, 2022 /PRNewswire/ -- OPEN Health is pleased to announce the appointment of David Thompson, PhD, as Chief Executive Officer for Evidence & Access. David joins OPEN Health with a wealth of global experience in this area. He is a health economist by training, with 25+ years of experience conducting...
Progresses Made in Series of Studies of Prevention and Control of COVID-19 with Lianhua Qingwen Capsules
SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ -- On March 19, the Media Briefing on Prevention and Control of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese medicine developed and produced by Yiling Pharmaceutical, was convened in Shijiazhuang City, Hebei Province, at which the in vitro experimental results of Lianhua Qingwen Capsules against SARS-CoV-2 Omicron variant by Guangzhou Institute of Respiratory...
Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HPV Vaccine CandidatesFocus on In-house Research and Development of Novel Vaccines TAIZHOU, China, March 21, 2022 /PRNewswire/ -- The China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or...
AIA REPORTS ON SIGNIFICANT ENVIRONMENTAL, SOCIAL, AND GOVERNANCE ACHIEVEMENTS IN 2021
HONG KONG, March 21, 2022 /PRNewswire/ -- AIA Group Limited (the "Company", and together with its subsidiaries, "AIA" or the "Group"; stock code: 1299), the largest pan-Asian life and health insurer, issued its 2021 Environmental, Social and Governance (ESG) report Sustaining Healthier, Longer, Better Lives, highlighting the acceleration of its ESG Strategy. Lee Yuan Siong, AIA...
